Emerging drugs for endometriosis

Expert Opinion on Emerging Drugs

Volumn 13, Issue 4, 2008, Pages 547-571

  Guo, Sun Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clinical trials; Drug; Endometriosis; Pain; Treatment

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ASOPRISNIL; ATORVASTATIN; CETRORELIX; CYCLOOXYGENASE 2 INHIBITOR; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; INFLIXIMAB; LETROZOLE; LEVONORGESTREL; MEDROXYPROGESTERONE; MIFEPRISTONE; NBI 56418; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PRINABEREL; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; ROFECOXIB; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ULIPRISNIL ACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

CLINICAL TRIAL; DRUG MECHANISM; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE SUBFERTILITY; HUMAN; NONHUMAN; PELVIS PAIN SYNDROME; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; ENDOMETRIOSIS; FEMALE; HUMANS; INFERTILITY, FEMALE; PAIN; RECURRENCE; TREATMENT OUTCOME;

EID: 58149214232     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210802548360     Document Type: Review

References (293)

1. Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991;6(4):544-9
2. Olive DL, Schwartz LB. Endometriosis. N Engl J Med 1993;328(24):1759-69
3. Farquhar CM. Extracts from the 'clinical evidence': endometriosis. BMJ 2000;320(7247):1449-52
4. Boling RO, Abbasi R, Ackerman G, et al. Disability from endometriosis in the United States Army. J Reprod Med 1988;33(1):49-52
5. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984-1992. Am J Public Health 1996;86(2):195-9
6. Sampson J. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927;14:422-69
7. Witz CA. Current concepts in the pathogenesis of endometriosis. Clin Obstet Gynecol 1999;42(3):566-85
8. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann NY Acad Sci 2003;997:229-39
9. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997;67:817-21
10. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345(4):266-75
11. Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005;4:CD004753
12. Candiani M. Current guidelines for treatment of endometriosis without laparoscopy. Drugs Today (Barc) 2005;41(Suppl A):11-5
13. Kennedy S, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20(10):2698-704 • This is an excellent assessment and summarization of all evidence regarding the diagnosis and treatment of endometriosis.
14. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59(3):511-5
15. Kiilholma P, et al. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 1995;64(5):903-8
16. Lessey BA. Medical management of endometriosis and infertility. Fertil Steril 2000;73(6):1089-96
17. Bulun SE, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57(3):359-83 • A comprehensive and in-depth review on the pathogenesis of endometriosis, and the first formal formulation of a positive-feedback loop in endometriosis.
18. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68(3):393-401
19. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364(9447):1789-99 • An excellent review on various aspects of endometriosis.
20. Bulun SE, et al. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update 2000;6(5):413-8
21. Noble LS, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996;81(1):174-9
22. Zeitoun K, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998;83(12):4474-80
23. Bateman BG, Kolp LA, Mills S. Endoscopic versus laparotomy management of endometriomas. Fertil Steril 1994;62(4):690-5
24. Jones KD, Sutton C. Patient satisfaction and changes in pain scores after ablative laparoscopic surgery for stage III-IV endometriosis and endometriotic cysts. Fertil Steril 2003;79(5):1086-90
25. Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004;16(4):299-303
26. Evers JL, et al. Management of recurrent endometriosis, in Progress in the management of endometriosis. Couinho E, Spinola P, DeMoura LH, Editors, 1995, Partheon: London:291-7
27. Ragni G, et al. Damage to ovarian reserve associated with laparoscopic excision of endometriomas: a quantitative rather than a qualitative injury. Am J Obstet Gynecol 2005;193(6):1908-14
28. Hachisuga T, Kawarabayashi T. Histopathological analysis of laparoscopically treated ovarian endometriotic cysts with special reference to loss of follicles. Hum Reprod 2002;17(2):432-5
29. Somigliana E, et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod 2003;18(11):2450-3
30. Somigliana E, et al. Does laparoscopic removal of nonendometrioric benign ovarian cysts affect ovarian reserve? Acta Obstet Gynecol Scand 2006;85(1):74-7
31. Candiani M, et al. Ovarian recovery after laparoscopic enucleation of ovarian cysts: insights from echography short-term postsurgical follow-up. J Minim Invasive Gynecol 2005;12(5):409-14
32. Yuan L, et al. Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence. Fertil Steril 2008;66(1):59-62 • The first report of a biomarker for recurrence of ovarian endometriomas with estimated sensitivity and specificity.
33. Shen F, et al. Immunoreactivity of progesterone receptor isoform B and nuclear factor kappa-B as biomarkers for recurrence of ovarian endometriomas. Am J Obstet Gynecol 2008, Jun 11. [Epub ahead of print]
34. Corson SL, Bolognese RJ. Ibuprofen therapy for dysmenorrhea. J Reprod Med 1978;20(5):246-52
35. Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005;17(4):359-65
36. Takayama K, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998;69(4):709-13
37. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72(6):961-9
38. Ailawadi RK, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81(2):290-6
39. Donnez J, et al. Surgical management of endometriosis. Best Pract Res Clin Obstet Gynaecol 2004;18(2):329-48
40. Hurxthal LM, Smith AT. Treatment of endometriosis and other gynecologic conditions with large doses of estrogens. N Engl J Med 1952;247(10):339-43
41. Kistner RW. The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 1958;75(2):264-78
42. Greenhill JP. Use of oral and intrauterine contraceptives. An international panel reports. Int Surg 1968;49(4):312-8
43. Friedlander RL. The treatment of endometriosis with Danazol. J Reprod Med 1973;10(4):197-9
44. Andrews MC, Wentz AC. The effects of danazol on gonadotropins and steroid blood levels in normal and anovulatory women. Am J Obstet Gynecol 1975;121(6):817-28
45. Dmowski WP, Cohen MR. Treatment of endometriosis with an antigonadotropin, Danazol. A laparoscopic and histologic evaluation. Obstet Gynecol 1975;46(2):147-54
46. Lemay A, Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 1982;38(3):376-9
47. Guo SW, Olive DL. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest 2007;64(1):24-35
48. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28(5):575-87
49. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20(3):321-44
50. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005;5(6):343-57
51. Van Der Laan S, Meijer OC. Pharmacology of glucocorticoids: beyond receptors. Eur J Pharmacol 2008;585(2-3):483-91
52. Wu Y, et al. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 2006;1(2):106-11
53. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2006;86(5 Suppl):S18-27
54. Liu X, Guo SW. Dysmenorrhea: Risk factors in women with endometriosis. Women's Health Future Med 2008;4(4):399-411
55. Riley JL 3rd, et al. A meta-analytic review of pain perception across the menstrual cycle. Pain 1999;81(3):225-35
56. Rodgers AK, Falcone T. Treatment strategies for endometriosis. Expert Opin Pharmacother 2008;9(2):243-55
57. Berkley KJ, et al. Endometriosis-induced vaginal hyperalgesia in the rat: effect of estropause, ovariectomy, and estradiol replacement. Pain 2007;132(Suppl 1):S150-9
58. Evrard HC, Balthazart J. Aromatization of androgens into estrogens reduces response latency to a noxious thermal stimulus in male quail. Horm Behav 2004;45(3):181-9
59. Evrard HC, Balthazart J. Aromatase (estrogen synthase) activity in the dorsal horn of the spinal cord: functional implications. Ann NY Acad Sci 2003;1007:263-71
60. Anaf V, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000;15(8):1744-50 • The first report on nerve fiber distribution and density in endometriosis.
61. Anaf V, et al. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod 2002;17(7):1895-900
62. Tokushige N, et al. High density of small nerve fibres in the functional layer of the endometrium in women with endometriosis. Hum Reprod 2006;21(3):782-7
63. Tokushige N, et al. Nerve fibres in peritoneal endometriosis. Hum Reprod 2006;21(11):3001-7
64. Tokushige N, et al. Different types of small nerve fibers in eutopic endometrium and myometrium in women with endometriosis. Fertil Steril 2007;88(4):795-803
65. Tokushige N, et al. Effects of hormonal treatment on nerve fibers in endometrium and myometrium in women with endometriosis. Fertil Steril 2007, Nov 30. [Epub ahead of print]
66. Al-Jefout M, et al. A pilot study to evaluate the relative efficacy of endometrial biopsy and full curettage in making a diagnosis of endometriosis by the detection of endometrial nerve fibers. Am J Obstet Gynecol 2007;197(6):578 e1-4
67. Giamberardino MA, et al. Influence of endometriosis on pain behaviors and muscle hyperalgesia induced by a ureteral calculosis in female rats. Pain 2002;95(3):247-57 • A very interesting study on the effect of endometriosis on pain behaviors in rats.
68. Cason AM, Samuelsen CL. Berkley KJ. Estrous changes in vaginal nociception in a rat model of endometriosis. Horm Behav 2003;44(2):123-31
69. Winnard KP, Dmitrieva N, Berkley KJ. Cross-organ interactions between reproductive, gastrointestinal, and urinary tracts: modulation by estrous stage and involvement of the hypogastric nerve. Am J Physiol Regul Integr Comp Physiol 2006;291(6):R1592-601
70. Zhang G, et al. Endometriosis as a neurovascular condition: estrous variations in innervation, vascularization, and growth factor content of ectopic endometrial cysts in the rat. Am J Physiol Regul Integr Comp Physiol 2008;294(1):R162-71
71. Brinkert W, et al. Dysmenorrhoea is associated with hypersensitivity in the sigmoid colon and rectum. Pain 2007;132(Suppl 1):S46-51
72. Endometriosis and infertility. Fertil Steril 2006;86(5 Suppl): p. S156-60
73. Moen MH. Is a long period without childbirth a risk factor for developing endometriosis? Hum Reprod 1991;6(10):1404-7
74. Moen MH, Muus KM. Endometriosis in pregnant and non-pregnant women at tubal sterilization. Hum Reprod 1991;6(5):699-702
75. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24(2):235-58 • A comprehensive and excellent review on the epidemiology of endometriosis.
76. Jansen RP. Minimal endometriosis and reduced fecundability: prospective evidence from an artificial insemination by donor program. Fertil Steril 1986;46(1):141-3
77. Portuondo JA, et al. Early conception in patients with untreated mild endometriosis. Fertil Steril 1983;39(1):22-5
78. Rodriguez-Escudero FJ, et al. Does minimal endometriosis reduce fecundity? Fertil Steril 1988;50(3):522-4
79. Marcoux S, Maheux R, Berube S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 1997;337(4):217-22
80. Parazzini F. Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi. Hum Reprod 1999;14(5):1332-4
81. Leyendecker G, et al. Uterine hyperperistalsis and dysperistalsis as dysfunctions of the mechanism of rapid sperm transport in patients with endometriosis and infertility. Hum Reprod 1996;11(7):1542-51
82. Lessey BA, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab 1994;79(2):643-9
83. Gui Y, et al. Regulation of HOXA-10 and its expression in normal and abnormal endometrium. Mol Hum Reprod 1999;5(9):866-73
84. Taylor HS, et al. HOX gene expression is altered in the endometrium of women with endometriosis. Hum Reprod 1999;14(5):1328-31
85. Wu Y, et al. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 2005;193(2):371-80 • The first paper gives evidence for an epigenetic aberration in endometriosis and suggests that endometriosis may be an epigenetic disease.
86. Kim JJ, et al. Altered expression of HOXA10 in endometriosis: potential role in decidualization. Mol Hum Reprod 2007;13(5):323-32
87. Kao LC, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 2003;144(7):2870-81
88. Saito H, et al. Endometriosis and oocyte quality. Gynecol Obstet Invest 2002;53(Suppl 1):46-51
89. Toya M, et al. Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertil Steril 2000;73(2):344-50
90. Nakahara K, et al. Incidence of apoptotic bodies in membrana granulosa of the patients participating in an in vitro fertilization program. Fertil Steril 1997;67(2):302-8
91. Garcia-Velasco JA, Arici A. Is the endometrium or oocyte/embryo affected in endometriosis? Hum Reprod 1999;14(Suppl 2):77-89
92. Fujino K, et al. Survivin gene expression in granulosa cells from infertile patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 2008;89(1):60-5
93. Trinder J, Cahill DJ. Endometriosis and infertility: the debate continues. Hum Fertil (Camb) 2002;5(1 Suppl):S21-7
94. Mahmood TA, Templeton A. Folliculogenesis and ovulation in infertile women with mild endometriosis. Hum Reprod 1991;6(2):227-31
95. Schenken RS, et al. Etiology of infertility in monkeys with endometriosis: luteinized unruptured follicles, luteal phase defects, pelvic adhesions, and spontaneous abortions. Fertil Steril 1984;41(1):122-30
96. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001;75(1):1-10
97. Wu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol 2003;49(5):285-96
98. Wu MH, et al. Endometriosis: disease pathophysiology and the role of prostaglandins. Expert Rev Mol Med 2007;9(2):1-20
99. Yuan L, et al. COX-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence. Fertil Steril 2008; In press
100. Yamamoto T, et al. Evidence for estrogen synthesis in adenomyotic tissues. Am J Obstet Gynecol 1993;169(3):734-8
101. Noble LS, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82(2):600-6
102. Kitawaki J, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57(3):514-9
103. Yano S, Ikegami Y Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung 1996;46(2):192-5
104. Kudoh M, et al. Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol 1997;63(1-3):75-80
105. Dassen H, et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 2007;22(12):3148-58
106. Shippen ER, West WJ, Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81(5):1395-8
107. Razzi S, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. Bjog 2004;111(2):182-4
108. Fatemi HM, et al. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 2005;11(4):455-7
109. Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007;109(6):1421-3
110. Amsterdam LL, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005;84(2):300-4
111. Hefler LA, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 2005;84(4):1033-6
112. Remorgida V, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007;88(3):724-6
113. Remorgida V, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust NZ J Obstet Gynaecol 2007;47(3):222-5
114. Parwardhan S, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008;115(7):818-22
115. Soysal S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19(1):160-7
116. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85(5):1307-18
117. Khazaei M, Montaseri A, Casper RF. Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix. Fertil Steril 2008
118. Reissmann T, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000;6(4):322-31
119. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358(9295):1793-803
120. Mihalyi A, et al. Emerging drugs in endometriosis. Expert Opin Emerg Drugs 2006;11(3):503-24
121. Fedele L, et al. New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs 2008;17(8):1187-202
122. D'Hooghe TM, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod 2006;74(1):131-6
123. Kupker W, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5(1):12-6
124. Chwalisz K, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26(3):423-38 • An excellent review on selective progesterone receptor modulators and their possible use in endometriosis.
125. Kettel LM, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65(1):23-8
126. Kettel LM, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178(6):1151-6
127. Kettel LM, et al. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9(Suppl 1):116-20
128. Kettel LM, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56(3):402-7
129. Tjaden B, et al. Time-related effects of RU486 treatment in experimentally induced endometriosis in the rat. Fertil Steril 1993;59(2):437-40
130. Wu Y, Guo SW. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 2006;62(4):193-205
131. Attardi BJ, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188(1-2):111-23
132. Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003;68(10-13):1005-11
133. Dukes M, et al. Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the utetus in ovariectomized monkeys. J Endocrinol 1992;1352:239-47
134. Dukes M, Waterton JC, Wakeling AE. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 1993;138(2):203-10
135. Johnston SR. Fulvestrant (AstraZeneca). Curr Opin Investig Drugs 2002;3(2):305-12
136. Yao Z, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg 2005;18(4):177-83
137. Yavuz E, et al. Genistein causes regression of endometriotic implants in the rat model. Fertil Steril 2007;88(4 Suppl):1129-34
138. Stratton P, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008;111(1):88-96
139. Cvoro A, et al. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008;180(1):630-6
140. Harris HA, et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20(4):936-41
141. Jackson KS, et al. The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity. Reprod Sci 2007;14(2):137-50
142. Hapangama DK, et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Hum Reprod 2008;23(7):1511-9
143. Brandenberger AW, et al. Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod 1999;5(7):651-5
144. Bukulmez O, et al. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology 2008;149(3):1190-204
145. Montagna P, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril 2008;90(1):156-64
146. Xue Q, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 2007;77(4):681-7
147. Ota H, et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16(3):561-6
148. Chishima F, et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002;48(1):50-6
149. Bartley J, et al. [COX-2-expression in extragenital endometriosis lesions as a novel therapeutical approach?]. Zentralbl Gynakol 2003;125(7-8):252-5
150. Fagotti A, et al. Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters. Hum Reprod 2004; 19(2):393-7
151. Matsuzaki S, et al. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril 2004;82(5):1309-15
152. Wu MH, et al. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 2005;90(1):286-95
153. Matsuzaki S, et al. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 2004;82(6):1609-15
154. Hull ML, et al. Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 2005;20(2):350-8
155. Dogan E, et al. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 2004;82(Suppl 3):1115-20
156. Efstathiou JA, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005;83(1):171-81
157. Ozawa Y, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 2006;86(Suppl 4):1146-51
158. Laschke MW, et al. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007;87(1):163-71
159. Cobellis L, et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116(1):100-2
160. Solomon SD, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352(11):1071-80
161. Bresalier RS, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
162. Schoonjans K, et al. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8(3):159-66
163. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43(4):527-50
164. Ricote M, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391(6662):79-82
165. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391(6662):82-6
166. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355(9208):1008-10
167. Pritts EA, et al. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro J Clin Endocrinol Metab 2002;87(4):1841-4
168. Wanichkul T, et al. Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 2003;79(Suppl 1):763-9
169. Akoum A, Lemay A, Maheux R. Estradiol and interleukin-1beta exert a synergistic stimulatory effect on the expression of the chemokine regulated upon activation, normal T cell expressed, and secreted in endometriotic cells. J Clin Endocrinol Metab 2002;87(12):5785-92
170. Pritts EA, et al. Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 2003;80(2):415-20
171. Aytan H, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust NZ J Obstet Gynaecol 2007;47(4):321-5
172. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82(Suppl 3):1008-13
173. Demirturk F, et al. Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13(1):58-62
174. Lebovic DI, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88(4 Suppl):1108-19
175. Hornung D, et al. Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 2003;55(1):20-4
176. Ohama Y, et al. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 2008;89(2):311-7
177. Meade EA, et al. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274(12):8328-34
178. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405(6785):421-4
179. Ebisch IM, et al. Possible role of the plasminogen activation system in human subfertility. Fertil Steril 2007;87(3):619-26
180. Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89
181. Agic A, et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci 2007;14(5):486-97
182. Sawatsri S, et al. Retinoic acid suppresses interleukin-6 production in human endometrial cells. Fertil Steril 2000;73(5):1012-9
183. Bain DL, et al. Nuclear receptor structure: implications for function. Annu Rev Physiol 2007;69:201-20
184. Wu Y, Guo SW. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril 2008
185. Available from: www.ClinicalTrials.gov accessed 31 August 2008
186. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95
187. Dahabreh IJ, Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008;5(2):116-20
188. Franzoni F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90(2-3):317-21
189. Piotrowski PC, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod 2006;75(1):107-11
190. Masukawa T, et al. Cytologic detection of minute ovarian, endometrial and breast carcinomas, with emphasis on clinical-pathological approaches. Acta Cytol 1973;17(4):316-9
191. Wassmann S, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo Arterioscler Thromb Vasc Biol 2002;22(2):300-5
192. Esfandiari N, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril 2007;87(2):257-62
193. Oktem M, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 2007;22(5):1474-80
194. Guo SW. Nuclear Factor-kappaB (NF-kappaB): An Unsuspected Major Culprit in the Pathogenesis of Endometriosis That is Still At Large? Gynecol Obstet Invest 2006;63(2):71-97
195. D'Antonio M, et al. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 2000;48(2):81-98
196. Barrier BF, et al. Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 2004;81(Suppl 1):775-9
197. Falconer H, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 2006;21(7):1856-62
198. Falconer H, et al. Effects of anti-TNF-mAb treatment on pregnancy in baboons with induced endometriosis. Fertil Steril 2008;89(5 Suppl):1537-45
199. Koninckx PR, et al. Anti-TNF-{alpha} treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008
200. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85
201. Askling J, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52(7):1986-92
202. Askling J, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1421-6
203. Askling J, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66(10):1339-44
204. Hill JA. Immunology and endometriosis. Fact, artifact, or epiphenomenon? Obstet Gynecol Clin North Am 1997;24(2):291-306
205. Seli E, Arici A. Endometriosis: interaction of immune and endocrine systems. Semin Reprod Med 2003;21(2):135-44 • A comprehensive review on the immunology of endometriosis.
206. Somigliana E, et al. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod 1999;14(12):2944-50
207. Ingelmo JM, Quereda F, Acien P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Fertil Steril 1999;71(5):907-11
208. Keenan JA, et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999;72(1):135-41
209. Aytan H, et al. Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 2007;87(3):698-701
210. Uygur D, et al. Leflunomide-an immunomodulator - induces regression of endometrial explants in a rat model of endometriosis. J Soc Gynecol Investig 2006;13(5):378-83
211. Sel'kov SA, Pavlov RV. Comparative efficiency of intraperitoneal interleukine-2 and interferon-A in rats with experimental endometriosis. Bull Exp Biol Med 2007;143(3):363-7
212. Ocal G, et al. Efficacy of levamisole on experimental endometriosis. Int J Gynaecol Obstet 2007;99(1):38-42
213. Altintas D, et al. Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis. Fertil Steril 2007
214. Altintas D, et al. Efficacy of recombinant human interferon alpha-2b on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2008;139(1):95-9
215. Quereda F, et al. The effect of intraperitoneal interleukin-2 on surgically induced endometriosis in rats. Eur J Obstet Gynecol Reprod Biol 2008;136(2):243-8
216. Velasco I, et al. Intraperitoneal recombinant interleukin-2 activates leukocytes in rat endometriosis. J Reprod Immunol 2007;74(1-2):124-32
217. Laschke MW, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006;149(2):137-44
218. Acien P, et al. Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postopetative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 2002;78(4):705-11
219. Acien P, et al. GnRH analogues, transvaginal ultrasound-guided drainage and intracystic injection of recombinant interleukin-2 in the treatment of endometriosis. Gynecol Obstet Invest 2003;55(2):96-104
220. Acien P, et al. Treatment of endometriosis with transvaginal ultrasound-guided drainage under GnRH analogues and recombinant interleukin-2 left in the cysts. Gynecol Obstet Invest 2005;60(4):224-31
221. Velasco I, Campos A, Acien P. Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage, and intracystic recombinant interleukin-2. Fertil Steril 2005;83(4):873-7
222. Steinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril 1991;55(1):26-31
223. Steinleitner A, et al. Immunomodulation in the treatment of endometriosis-associated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril 1991;56(5):975-9
224. Nothnick WB, Curry TE, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 1994;31(2-3):151-62
225. Mohammadzadeh A, et al. Evaluation of the effect of pentoxifylline on white blood cell count in serum and peritoneal fluid in female rats with endometriosis. J Obstet Gynaecol Res 2008;34(3):307-13
226. Balasch J, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 1997;12(9):2046-50
227. Alborzi S, et al. A prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas. Fertil Steril 2004;82(6):1633-7
228. Kamencic H, Thiel JA. Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial. J Minim Invasive Gynecol 2008; 15(1):62-6
229. Creus M, et al. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod 2008
230. Pearson G, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22(2):153-83
231. Yoshino O, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol 2004;52(5):306-11
232. Yamauchi N, et al. Tumor necrosis factor-alpha induced the release of interleukin-6 from endometriotic stromal cells by the nuclear factor-kappaB and mitogen-activated protein kinase pathways. Fertil Steril 2004;82(Suppl 3):1023-8
233. Luo X, Ding L, Chegini N. Gonadotropin-releasing hormone and TGF-beta activate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells. Am J Physiol Endocrinol Metab 2004;287(5):E991-1001
234. Matsuzaki S, et al. DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil Steril 2005;84(Suppl 2):1180-90
235. Matsuzaki S, et al. DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection. Mol Hum Reprod 2004;10(10):719-28
236. Wu Y, et al. Transcriptional characterizations of differences between eutopic and ectopic endometrium. Endocrinology 2006;147(1):232-46 • This paper provides evidence that different subtypes of endometriosis have different gene expression profiles, which can be used to classify endometriosis based on molecular genetic data.
237. Hirata T, et al. Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. Endocrinology 2008;149(3):1260-7
238. Tagashira Y, et al. Interleukin-10 attenuates TNF-alpha-induced interleukin-6 production in endometriotic stromal cells. Fertil Steril 2008
239. Murk W, et al. ERK Activity in the Human Endometrium: Possible Roles in the Pathogenesis of Endometriosis. J Clin Endocrinol Metab 2008
240. Yoshino O, et al. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 2006;72(1-2):85-93
241. Kumar A, et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82(7):434-48
242. Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril 2002;77(5):861-70
243. Guo SW. Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest 2007;63(2):71-97
244. Gonzalez-Ramos R, et al. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod 2007;13(7):503-9 • The first demonstration that NF-κB is constitutively activated in endometriosis.
245. Lousse JC, et al. Increased activation of nuclear factor-kappa B (NF-kappaB) in isolated peritoneal macrophages of patients with endometriosis. Fertil Steril 2008;90(1):217-20
246. Grund EM, et al. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Mol Pharmacol 2008;73(5):1394-404
247. Gonzalez-Ramos R, et al. Agents blocking the nuclear factor-kappaB pathway are effective inhibitors of endometriosis in an in vivo experimental model. Gynecol Obstet Invest 2008;65(3):174-86
248. Nasu K, et al. Application of the nuclear factor-kappaB inhibitot BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab 2007;293(1):E16-23
249. Guney M, et al. Effect of caffeic acid phenethyl ester on the regression of endometrial explants in an experimental rat model. Reprod Sci 2007;14(3):270-9
250. Wu Y, Starzinski-Powitz A, Guo SW. Capsaicin Inhibits Proliferation of Endometriotic Cells in vitro Gynecol Obstet Invest 2008;66(1):59-62
251. Kalkhoven E, et al. Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor. J Biol Chem 1996;271(11):6217-24
252. Aggarwal BB, et al. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006;10(1):87-118
253. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270(42):24995-5000
254. Singh S, Natarajan K, Aggarwal BB. Capsaicin (8-methyl-N-vanillyl-6- nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J Immunol 1996;157(10):4412-20
255. Laird SM, et al. Expression of nuclear factor kappa B in human endometrium; role in the control of interleukin 6 and leukaemia inhibitory factor production. Mol Hum Reprod 2000;6(1):34-40
256. Page M, et al. Expression of nuclear factor kappa B components in human endometrium. J Reprod Immunol 2002;54(1-2):1-13
257. King AE, Critchley HO, Kelly RW. The NF-kappaB pathway in human endometrium and first trimester decidua. Mol Hum Reprod 2001;7(2):175-83
258. Wu Y, Starzinski-Powitz A, Guo SW. Prolonged stimulation with tumor necrosis factor-alpha induced partial methylation at PR-B promoter in immortalized epithelial-like endometriotic cells. Fertil Steril 2008;90(1):234-7
259. Rountree MR, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001;20(24):3156-65
260. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54
261. Attia GR, et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85(8):2897-902 • This study demonstrates clearly that PR-B is downregulated in endometriosis.
262. Wu Y, et al. Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. Fertil Steril 2007;87(1):24-32
263. Xue Q, et al. Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5′ CpG island in endometriosis. J Clin Endocrinol Metab 2007;92(8):3261-7
264. Izawa M, et al. An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells. Fertil Steril 2008;89(5 Suppl):1390-6
265. Wu Y, Guo SW. Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2007;135(1):88-93
266. Wu Y, Guo SW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2008;137(2):198-203
267. Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 2007;14(4):374-82
268. Prabhakar S, et al. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007;48(7):1371-7
269. Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 2008;89(1):246-50
270. Nap AW, et al. Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model. Hum Reprod 2004;19(10):2180-7
271. Mori T, et al. A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice. Anticancer Res 2002;22(6C):3985-8
272. Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20(4):503-10
273. Foyouzi N, et al. Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 2004;82(Suppl 3):1019-22
274. Santanam N, Murphy AA, Parthasarathy S. Macrophages, oxidation, and endometriosis. Ann NY Acad Sci 2002;955:183-98; discussion 19-200, 396-406
275. Nap AW, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89(3):1089-95
276. Hull ML, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88(6):2889-99
277. Becker CM, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84(Suppl 2):1144-55
278. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13(4):331-42
279. Becker CM, et al. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006;85(1):71-7
280. Nap AW, et al. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005;83(3):793-5
281. Becker CM, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172(2):534-44
282. Yagyu T, et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 2005;90(5):3017-21
283. Guney M, et al. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril 2008;89(4):934-42
284. Kayisli UA, et al. The broad-spectrum chemokine inhibitor NR58-3.14.3 suppresses the implantation and survival of human endometrial implants in the nude mice endometriosis model. Reprod Sci 2007;14(8):825-35
285. Vercellini P, et al. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod 2006
286. Liu X, Guo SW. Dysmenorrhea: risk factors in women with endometriosis. Women Health (Future Medicine) 2008;4(4):399-411
287. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd edition; 1994, Seattle: IASP Press
288. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
289. Donnez J, et al. Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum are two different entities. Fertil Steril 1996;66(3):362-8
290. Wren JD, Wu Y, Guo SW. A system-wide analysis of differentially expressed genes in ectopic and eutopic endometrium. Hum Reprod 2007;22(8):2093-102 • Based on gene expression profiles, this paper demonstrates the complexity of endometriosis, and makes the point that any claim that targeting a single gene or gene product would be enough to treat endometriosis should be carefully scrutinized.
291. Schadt EE, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 2005;37(7):710-7
292. Stratton P, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15(5):1092-9
293. Passaro MD, et al. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod 2003;18(9):1820-7